Pliant Therapeutics, Inc. (PLRX)
Nasdaq: PLRX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2018
Who owns Pliant Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Tang Capital Management, LLC holds 9.6% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D filed Mar 10, 2025 says.
Directors and officers
13
report now, of 23 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Tang Capital Management, LLC
SCHEDULE 13D · filed Mar 10, 2025 · Common Stock, par value $0.0001 per share
ADAR1 Capital Management, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
The Vanguard Group
SCHEDULE 13G/A · filed Jul 29, 2025 · Common Stock · reported falling below 5%
Redmile Group, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Kenneth Griffin
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share (the "Shares") · reported falling below 5%, from 5% in Feb 9, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 17, 2025 · Common Stock · reported falling below 5%
Woodline Partners LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 7.3% in Nov 14, 2025
Morgan Stanley
SCHEDULE 13G/A · filed Jan 8, 2026 · Common Stock · reported falling below 5%, from 6.1% in Aug 6, 2025
Fmr LLC
SCHEDULE 13G/A · filed Mar 7, 2025 · COMMON STOCK · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.7% in Sep 4, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed May 14, 2025 · COMMON STOCK · reported falling below 5%
Deep Track Capital, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.43% in Aug 14, 2025
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
What PLRX reports owning in othersstakes of 5% or more, and other ties
Pliant Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
4sales
0purchases
4sales on a scheduled plan
4people selling
$200,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Coulie Bernard | President and CEO | 1 | $100,000 | 1 | 0 | $0 |
| Cummings Keith Lamont | Chief Financial Officer | 1 | $0 | 1 | 0 | $0 |
| Kuo Minnie | Chief Operating Officer | 1 | $0 | 1 | 0 | $0 |
| Cheung Lily | Chief Human Resource Officer | 1 | $0 | 1 | 0 | $0 |